STRATA Skin Sciences Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for STRATA Skin Sciences.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Medical Equipment earnings growth | 16.4% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
SSKN: Future P/E Reassessment Will Create Opportunity Despite Nasdaq Delisting Risk
Analysts have revised their fair value estimate for STRATA Skin Sciences from $8.00 to $10.80, reflecting updated assumptions related to revenue growth, profit margin, a higher future P/E multiple, and a revised discount rate. What's in the News Nasdaq notified STRATA Skin Sciences that it is not in compliance with the minimum US$2,500,000 stockholders' equity requirement for continued listing on the Nasdaq Capital Market under Listing Rule 5550(b)(1), and granted an extension until February 16, 2026, after accepting the company’s compliance plan submitted on September 19, 2025 (Key Developments).Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt Sensibly?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Surges 36% Yet Its Low P/S Is No Reason For Excitement
Those holding STRATA Skin Sciences, Inc. ( NASDAQ:SSKN ) shares would be relieved that the share price has rebounded...There's No Escaping STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Muted Revenues Despite A 45% Share Price Rise
STRATA Skin Sciences, Inc. ( NASDAQ:SSKN ) shares have had a really impressive month, gaining 45% after a shaky period...CPT Reimbursement Expansion Will Augment Future Dermatology Opportunities
The consensus Analyst Price Target for STRATA Skin Sciences has been revised downward, primarily reflecting a notable decline in the Future P/E multiple, resulting in a reduction of fair value from $9.00 to $8.00. What's in the News STRATA Skin Sciences is collaborating with CMS to secure temporary reimbursement codes for its XTRAC excimer laser treatment, aiming to accelerate access to newly expanded reimbursement indications as early as the 2026 rule cycle.Benign Growth For STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Underpins Its Share Price
With a price-to-sales (or "P/S") ratio of 0.3x STRATA Skin Sciences, Inc. ( NASDAQ:SSKN ) may be sending very bullish...
Improved XTRAC Utilization And Expanded International Partnerships Will Secure Success
Strategic removal of underperforming units and partnerships with clinics enhance device utilization and revenue potential.Investors Don't See Light At End Of STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Tunnel And Push Stock Down 30%
The STRATA Skin Sciences, Inc. ( NASDAQ:SSKN ) share price has fared very poorly over the last month, falling by a...Is STRATA Skin Sciences (NASDAQ:SSKN) Weighed On By Its Debt Load?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Shares Lagging The Industry But So Is The Business
STRATA Skin Sciences, Inc.'s ( NASDAQ:SSKN ) price-to-sales (or "P/S") ratio of 0.3x might make it look like a strong...Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt In A Risky Way?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Price Is Right But Growth Is Lacking After Shares Rocket 25%
STRATA Skin Sciences, Inc. ( NASDAQ:SSKN ) shareholders are no doubt pleased to see that the share price has bounced...Health Check: How Prudently Does STRATA Skin Sciences (NASDAQ:SSKN) Use Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...We Think STRATA Skin Sciences (NASDAQ:SSKN) Has A Fair Chunk Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Stock Rockets 26% But Many Are Still Ignoring The Company
STRATA Skin Sciences, Inc. ( NASDAQ:SSKN ) shareholders have had their patience rewarded with a 26% share price jump in...Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt Sensibly?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as STRATA Skin Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 31 | -6 | -4 | -3 | N/A |
| 9/30/2025 | 31 | -11 | -4 | -2 | N/A |
| 6/30/2025 | 33 | -12 | -3 | -2 | N/A |
| 3/31/2025 | 34 | -9 | -1 | 0 | N/A |
| 12/31/2024 | 34 | -10 | -1 | 0 | N/A |
| 9/30/2024 | 33 | -9 | -2 | 1 | N/A |
| 6/30/2024 | 33 | -8 | -3 | -1 | N/A |
| 3/31/2024 | 33 | -11 | -4 | -1 | N/A |
| 12/31/2023 | 33 | -11 | -6 | -1 | N/A |
| 9/30/2023 | 35 | -7 | -6 | -2 | N/A |
| 6/30/2023 | 36 | -7 | -6 | 0 | N/A |
| 3/31/2023 | 37 | -6 | -6 | -1 | N/A |
| 12/31/2022 | 36 | -6 | -5 | -1 | N/A |
| 9/30/2022 | 35 | -6 | -4 | 0 | N/A |
| 6/30/2022 | 33 | -6 | -3 | 1 | N/A |
| 3/31/2022 | 31 | -3 | -3 | 1 | N/A |
| 12/31/2021 | 30 | -3 | -2 | 2 | N/A |
| 9/30/2021 | 28 | -2 | -2 | 1 | N/A |
| 6/30/2021 | 26 | -3 | -2 | 1 | N/A |
| 3/31/2021 | 22 | -6 | -1 | 2 | N/A |
| 12/31/2020 | 23 | -4 | 0 | 2 | N/A |
| 9/30/2020 | 25 | -4 | N/A | 3 | N/A |
| 6/30/2020 | 27 | -4 | 0 | 3 | N/A |
| 3/31/2020 | 31 | -3 | 0 | 2 | N/A |
| 12/31/2019 | 32 | -4 | -1 | 2 | N/A |
| 9/30/2019 | 31 | -3 | N/A | 2 | N/A |
| 6/30/2019 | 31 | -3 | N/A | 3 | N/A |
| 3/31/2019 | 31 | -3 | N/A | 3 | N/A |
| 12/31/2018 | 30 | -4 | N/A | 3 | N/A |
| 9/30/2018 | 31 | -9 | N/A | 4 | N/A |
| 6/30/2018 | 30 | -22 | N/A | 2 | N/A |
| 3/31/2018 | 31 | -21 | N/A | 3 | N/A |
| 12/31/2017 | 32 | -22 | N/A | 4 | N/A |
| 9/30/2017 | 30 | -18 | N/A | 4 | N/A |
| 6/30/2017 | 31 | -6 | N/A | 4 | N/A |
| 3/31/2017 | 30 | -4 | N/A | 3 | N/A |
| 12/31/2016 | 31 | -3 | N/A | 0 | N/A |
| 9/30/2016 | 33 | -3 | N/A | -1 | N/A |
| 6/30/2016 | 33 | -14 | N/A | -3 | N/A |
| 3/31/2016 | 26 | -22 | N/A | -5 | N/A |
| 12/31/2015 | 18 | -28 | N/A | -7 | N/A |
| 9/30/2015 | 9 | -34 | N/A | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if SSKN's forecast earnings growth is above the savings rate (3.5%).
Earnings vs Market: Insufficient data to determine if SSKN's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if SSKN's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if SSKN's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if SSKN's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SSKN's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/12 10:54 |
| End of Day Share Price | 2026/07/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
STRATA Skin Sciences, Inc. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | CG Capital |
| Jeffrey Cohen | Ladenburg Thalmann & Company |
| John Sullivan | Leerink Partners LLC |